Short Interest in Celularity Inc. (NASDAQ:CELU) Increases By 7.1%

Celularity Inc. (NASDAQ:CELU) was the recipient of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 395,600 shares, a growth of 7.1% from the December 31st total of 369,300 shares. Based on an average daily volume of 1,080,000 shares, the short-interest ratio is currently 0.4 days. Currently, 4.2% of the shares of the stock are sold short.

Celularity Stock Performance

Shares of NASDAQ CELU traded down $0.01 during mid-day trading on Tuesday, hitting $2.02. 19,401 shares of the stock were exchanged, compared to its average volume of 71,290. Celularity has a twelve month low of $1.30 and a twelve month high of $7.97. The stock’s fifty day simple moving average is $2.23 and its two-hundred day simple moving average is $2.56.

Celularity (NASDAQ:CELU) last issued its quarterly earnings data on Friday, December 6th. The company reported ($0.73) earnings per share (EPS) for the quarter. Celularity had a negative net margin of 72.72% and a negative return on equity of 119.53%.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.